Targeting the collecting duct water channel aquaporin 2 (AQP2) to the plasma membrane is essential for the maintenance of mammalian water homeostasis. The vasopressin V2 receptor (V2R), which is a GS protein-coupled receptor that increases intracellular cAMP levels, has a major role in this targeting process. Although a rise in cAMP levels and activation of protein kinase A are involved in facilitating the actions of V2R, studies in knockout mice and cell models have suggested that cAMP signalling pathways are not an absolute requirement for V2R-mediated AQP2 trafficking to the plasma membrane. In addition, although AQP2 phosphorylation is a known prerequisite for V2R-mediated plasma membrane targeting, none of the known AQP2 phosphorylation events appears to be rate-limiting in this process, which suggests the involvement of other factors; cytoskeletal remodelling has also been implicated. Notably, several regulatory processes and signalling pathways involved in AQP2 trafficking also have a role in the pathophysiology of autosomal dominant polycystic kidney disease, although the role of AQP2 in cyst progression is unknown. Here, we highlight advances in the field of AQP2 regulation that might be exploited for the treatment of water balance disorders and provide a rationale for targeting these pathways in autosomal dominant polycystic kidney disease.
Targeting of the collecting duct water channel aquaporin 2 (AQP2) to the plasma membrane is essential for the maintenance of mammalian water homeostasis.
Although vasopressin signalling via the GS protein-coupled vasopressin V2 receptor (V2R) is a major receptor-mediated pathway that modulates trafficking of AQP2 to the plasma membrane, this targeting can also occur independently of V2R.
The canonical V2R signalling pathway — increased cAMP levels, activation of protein kinase A (PKA) and AQP2 phosphorylation — cannot fully explain AQP2 plasma membrane targeting, and cAMP–PKA-independent pathways exist.
Novel regulators of AQP2 plasma membrane targeting that are independent of V2R and cAMP include A-kinase anchoring protein (AKAP)–PKA disruptors, Src inhibition, Wnt5a, fluconazole and epidermal growth factor receptor antagonists.
Research on the signalling networks and regulatory steps that govern AQP2 trafficking has identified promising pharmacological targets for water balance disorders.
Investigating plasma membrane targeting of AQP2 using agents that do not increase cellular proliferation and epithelial secretion is required to delineate the independent role of AQP2 in cyst progression in autosomal dominant polycystic kidney disease.
This is a preview of subscription content
Subscribe to Nature+
Get immediate online access to the entire Nature family of 50+ journals
Subscribe to Journal
Get full journal access for 1 year
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Nawata, C. M. & Pannabecker, T. L. Mammalian urine concentration: a review of renal medullary architecture and membrane transporters. J. Comp. Physiol. B 188, 899–918 (2018).
Sohara, E., Rai, T., Sasaki, S. & Uchida, S. Physiological roles of AQP7 in the kidney: lessons from AQP7 knockout mice. Biochim. Biophys. Acta 1758, 1106–1110 (2006).
Fenton, R. A. & Knepper, M. A. Mouse models and the urinary concentrating mechanism in the new millennium. Physiol. Rev. 87, 1083–1112 (2007).
Kortenoeven, M. L. & Fenton, R. A. Renal aquaporins and water balance disorders. Biochim. Biophys. Acta 1840, 1533–1549 (2014).
Cheung, P. W., Bouley, R. & Brown, D. Targeting the trafficking of kidney water channels for therapeutic benefit. Annu. Rev. Pharmacol. Toxicol. 60, 175–194 (2020).
Verbalis, J. G. Acquired forms of central diabetes insipidus: Mechanisms of disease. Best Pract. Res. Clin. Endocrinol. Metab. 34, 101449 (2020).
Torres, V. E. et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N. Engl. J. Med. 367, 2407–2418 (2012).
Torres, V. E. et al. Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial. Nephrol. Dial. Transpl. 33, 477–489 (2018).
Torres, V. E. et al. Tolvaptan in later-stage autosomal dominant polycystic kidney disease. N. Engl. J. Med. 377, 1930–1942 (2017).
Valtin, H., Schroeder, H. A., Benirschke, K. & Sokol, H. W. Familial hypothalamic diabetes insipidus in rats. Nature 196, 1109–1110 (1962).
Li, J. H. et al. A selective EP4 PGE2 receptor agonist alleviates disease in a new mouse model of X-linked nephrogenic diabetes insipidus. J. Clin. Invest. 119, 3115–3126 (2009).
Rieg, T. et al. Adenylyl cyclase 6 enhances NKCC2 expression and mediates vasopressin-induced phosphorylation of NKCC2 and NCC. Am. J. Pathol. 182, 96–106 (2013).
Mutig, K. et al. Demonstration of the functional impact of vasopressin signaling in the thick ascending limb by a targeted transgenic rat approach. Am. J. Physiol. Renal Physiol. 311, F411–F423 (2016).
Pedersen, N. B., Hofmeister, M. V., Rosenbaek, L. L., Nielsen, J. & Fenton, R. A. Vasopressin induces phosphorylation of the thiazide-sensitive sodium chloride cotransporter in the distal convoluted tubule. Kidney Int. 78, 160–169 (2010).
Mutig, K. et al. Vasopressin V2 receptor expression along rat, mouse, and human renal epithelia with focus on TAL. Am. J. Physiol. Renal Physiol. 293, F1166–F1177 (2007).
Welker, P. et al. Renal Na+-K+-Cl− cotransporter activity and vasopressin-induced trafficking are lipid raft-dependent. Am. J. Physiol. Renal Physiol. 295, F789–F802 (2008).
Sakuma, Y. et al. Differential effects of hyperosmolality on Na-K-ATPase and vasopressin-dependent cAMP generation in the medullary thick ascending limb and outer medullary collecting duct. Hypertens. Res. 28, 671–679 (2005).
Rieg, T. et al. Adenylate cyclase 6 determines cAMP formation and aquaporin-2 phosphorylation and trafficking in inner medulla. J. Am. Soc. Nephrol. 21, 2059–2068 (2010).
Star, R. A., Nonoguchi, H., Balaban, R. & Knepper, M. A. Calcium and cyclic adenosine monophosphate as second messengers for vasopressin in the rat inner medullary collecting duct. J. Clin. Invest. 81, 1879–1888 (1988).
Marples, D., Christensen, B. M., Frokiaer, J., Knepper, M. A. & Nielsen, S. Dehydration reverses vasopressin antagonist-induced diuresis and aquaporin-2 downregulation in rats. Am. J. Physiol. 275, F400–F409 (1998).
Su, W., Cao, R., Zhang, X. Y. & Guan, Y. Aquaporins in the kidney: physiology and pathophysiology. Am. J. Physiol. Renal. Physiol. 318, F193–F203 (2019).
Zhang, X. Y., Wang, B. & Guan, Y. F. Nuclear receptor regulation of aquaporin-2 in the kidney. Int. J. Mol. Sci. 17, 1105 (2016).
Li, S. et al. Bile acid G protein-coupled membrane receptor TGR5 modulates aquaporin 2-mediated water homeostasis. J. Am. Soc. Nephrol. 29, 2658–2670 (2018).
Li, C. et al. Molecular mechanisms of angiotensin II stimulation on aquaporin-2 expression and trafficking. Am. J. Physiol. Renal Physiol. 300, F1255–F1261 (2011).
Bouley, R. et al. Calcitonin has a vasopressin-like effect on aquaporin-2 trafficking and urinary concentration. J. Am. Soc. Nephrol. 22, 59–72 (2011).
Yano, Y. et al. Aquaporin 2 expression increased by glucagon in normal rat inner medullary collecting ducts. Am. J. Physiol. Renal Physiol. 296, F54–F59 (2009).
Chu, J. Y. et al. Phenotypes developed in secretin receptor-null mice indicated a role for secretin in regulating renal water reabsorption. Mol. Cell Biol. 27, 2499–2511 (2007).
Lee, Y. J. et al. Increased AQP2 targeting in primary cultured IMCD cells in response to angiotensin II through AT1 receptor. Am. J. Physiol. Renal Physiol. 292, F340–F350 (2007).
Olesen, E. T., Rutzler, M. R., Moeller, H. B., Praetorius, H. A. & Fenton, R. A. Vasopressin-independent targeting of aquaporin-2 by selective E-prostanoid receptor agonists alleviates nephrogenic diabetes insipidus. Proc. Natl Acad. Sci. USA 108, 12949–12954 (2011).
Jung, H. J. & Kwon, T. H. Molecular mechanisms regulating aquaporin-2 in kidney collecting duct. Am. J. Physiol. Renal Physiol. 311, F1318–F1328 (2016).
Sun, T. X. et al. Aquaporin-2 localization in clathrin-coated pits: inhibition of endocytosis by dominant-negative dynamin. Am. J. Physiol. Renal Physiol. 282, F998–F1011 (2002).
Moeller, H. B., Knepper, M. A. & Fenton, R. A. Serine 269 phosphorylated aquaporin-2 is targeted to the apical membrane of collecting duct principal cells. Kidney Int. 75, 295–303 (2009).
Wang, W. L. et al. Rab7 involves Vps35 to mediate AQP2 sorting and apical trafficking in collecting duct cells. Am. J. Physiol. Renal Physiol. 318, F956–F970 (2020).
Vossenkamper, A. et al. Microtubules are needed for the perinuclear positioning of aquaporin-2 after its endocytic retrieval in renal principal cells. Am. J. Physiol. Cell Physiol. 293, C1129–C1138 (2007).
Tajika, Y. et al. Aquaporin-2 is retrieved to the apical storage compartment via early endosomes and phosphatidylinositol 3-kinase-dependent pathway. Endocrinology 145, 4375–4383 (2004).
Lee, M. S., Choi, H. J., Park, E. J., Park, H. J. & Kwon, T. H. Depletion of vacuolar protein sorting-associated protein 35 is associated with increased lysosomal degradation of aquaporin-2. Am. J. Physiol. Renal Physiol. 311, F1294–F1307 (2016).
Nedvetsky, P. I. et al. A role of myosin Vb and Rab11-FIP2 in the aquaporin-2 shuttle. Traffic 8, 110–123 (2007).
Yui, N. et al. Basolateral targeting and microtubule-dependent transcytosis of the aquaporin-2 water channel. Am. J. Physiol. Cell Physiol. 304, C38–C48 (2013).
Bouley, R., Yui, N., Terlouw, A., Cheung, P. W. & Brown, D. Chlorpromazine induces basolateral aquaporin-2 accumulation via F-actin depolymerization and blockade of endocytosis in renal epithelial cells. Cells 9, 1057 (2020).
Deshpande, V. et al. Phosphoproteomic identification of vasopressin V2 receptor-dependent signaling in the renal collecting duct. Am. J. Physiol. Renal Physiol. 317, F789–F804 (2019).
Hoffert, J. D., Pisitkun, T., Wang, G., Shen, R. F. & Knepper, M. A. Quantitative phosphoproteomics of vasopressin-sensitive renal cells: regulation of aquaporin-2 phosphorylation at two sites. Proc. Natl Acad. Sci. USA 103, 7159–7164 (2006).
Hoffert, J. D. et al. Vasopressin-stimulated increase in phosphorylation at Ser269 potentiates plasma membrane retention of aquaporin-2. J. Biol. Chem. 283, 24617–24627 (2008).
Xie, L. et al. Quantitative analysis of aquaporin-2 phosphorylation. Am. J. Physiol. Renal Physiol. 298, F1018–F1023 (2010).
Moeller, H. B., Praetorius, J., Rutzler, M. R. & Fenton, R. A. Phosphorylation of aquaporin-2 regulates its endocytosis and protein-protein interactions. Proc. Natl Acad. Sci. USA 107, 424–429 (2010).
Wang, P. J. et al. Vasopressin-induced serine 269 phosphorylation reduces Sipa1l1 (signal-induced proliferation-associated 1 like 1)-mediated aquaporin-2 endocytosis. J. Biol. Chem. 292, 7984–7993 (2017).
Roche, J. V., Nesverova, V., Olsson, C., Deen, P. M. & Tornroth-Horsefield, S. Structural insights into AQP2 targeting to multivesicular bodies. Int. J. Mol. Sci. 20, 5351 (2019).
Roche, J. V. & Tornroth-Horsefield, S. Aquaporin protein-protein interactions. Int. J. Mol. Sci. 18, 2255 (2017).
Roche, J. V. et al. Phosphorylation of human aquaporin 2 (AQP2) allosterically controls its interaction with the lysosomal trafficking protein LIP5. J. Biol. Chem. 292, 14636–14648 (2017).
Choi, H. J. et al. Sorting nexin 27 regulates the lysosomal degradation of aquaporin-2 protein in the kidney collecting duct. Cells 9, 1208 (2020).
Kamsteeg, E. J. et al. Short-chain ubiquitination mediates the regulated endocytosis of the aquaporin-2 water channel. Proc. Natl Acad. Sci. USA 103, 18344–18349 (2006).
Trimpert, C. et al. NDFIP allows NEDD4/NEDD4L-induced AQP2 ubiquitination and degradation. PLoS ONE 12, e0183774 (2017).
Lee, Y. J. et al. E3 ubiquitin-protein ligases in rat kidney collecting duct: response to vasopressin stimulation and withdrawal. Am. J. Physiol. Renal Physiol. 301, F883–F896 (2011).
Medvar, B., Raghuram, V., Pisitkun, T., Sarkar, A. & Knepper, M. A. Comprehensive database of human E3 ubiquitin ligases: application to aquaporin-2 regulation. Physiol. Genomics 48, 502–512 (2016).
Wu, Q. et al. CHIP regulates aquaporin-2 quality control and body water homeostasis. J. Am. Soc. Nephrol. 29, 936–948 (2018).
Centrone, M. et al. AQP2 abundance is regulated by the E3-ligase CHIP Via HSP70. Cell Physiol. Biochem. 44, 515–531 (2017).
Dema, A. et al. Cyclin-dependent kinase 18 controls trafficking of aquaporin-2 and its abundance through ubiquitin ligase STUB1, which functions as an AKAP. Cells 9, 673 (2020).
Murali, S. K., Aroankins, T. S., Moeller, H. B. & Fenton, R. A. The deubiquitylase USP4 interacts with the water channel AQP2 to modulate its apical membrane accumulation and cellular abundance. Cells 8, 265 (2019).
Moeller, H. B., Aroankins, T. S., Slengerik-Hansen, J., Pisitkun, T. & Fenton, R. A. Phosphorylation and ubiquitylation are opposing processes that regulate endocytosis of the water channel aquaporin-2. J. Cell Sci. 127, 3174–3183 (2014).
Moeller, H. B. et al. Regulation of the water channel aquaporin-2 via 14-3-3theta and -zeta. J. Biol. Chem. 291, 2469–2484 (2016).
Vukicevic, T. et al. Fluconazole increases osmotic water transport in renal collecting duct through effects on aquaporin-2 trafficking. J. Am. Soc. Nephrol. 30, 795–810 (2019).
Loo, C. S. et al. Quantitative apical membrane proteomics reveals vasopressin-induced actin dynamics in collecting duct cells. Proc. Natl Acad. Sci. USA 110, 17119–17124 (2013).
Simon, H., Gao, Y., Franki, N. & Hays, R. M. Vasopressin depolymerizes apical F-actin in rat inner medullary collecting duct. Am. J. Physiol. 265, C757–C762 (1993).
Chou, C. L. et al. Non-muscle myosin II and myosin light chain kinase are downstream targets for vasopressin signaling in the renal collecting duct. J. Biol. Chem. 279, 49026–49035 (2004).
Klussmann, E. et al. An inhibitory role of Rho in the vasopressin-mediated translocation of aquaporin-2 into cell membranes of renal principal cells. J. Biol. Chem. 276, 20451–20457 (2001).
Ranieri, M. et al. The vasopressin receptor 2 mutant R137L linked to the nephrogenic syndrome of inappropriate antidiuresis (NSIAD) signals through an alternative pathway that increases AQP2 membrane targeting independently of S256 phosphorylation. Cells 9, 1354 (2020).
Feldman, B. J. et al. Nephrogenic syndrome of inappropriate antidiuresis. N. Engl. J. Med. 352, 1884–1890 (2005).
Lei, L. et al. Manganese promotes intracellular accumulation of AQP2 via modulating F-actin polymerization and reduces urinary concentration in mice. Am. J. Physiol. Renal Physiol. 314, F306–F316 (2018).
Li, W. et al. Ezrin directly interacts with AQP2 and promotes its endocytosis. J. Cell Sci. 130, 2914–2925 (2017).
Neisch, A. L. & Fehon, R. G. Ezrin, radixin and moesin: key regulators of membrane-cortex interactions and signaling. Curr. Opin. Cell Biol. 23, 377–382 (2011).
Dransfield, D. T. et al. Ezrin is a cyclic AMP-dependent protein kinase anchoring protein. EMBO J. 16, 35–43 (1997).
Brunton, L. L., Hayes, J. S. & Mayer, S. E. Functional compartmentation of cyclic AMP and protein kinase in heart. Adv. Cyclic Nucleotide Res. 14, 391–397 (1981).
Knepper, M. A., Kwon, T. H. & Nielsen, S. Molecular physiology of water balance. N. Engl. J. Med. 373, 196 (2015).
Nedvetsky, P. I. et al. in Aquaporins. Handbook of Experimental Pharmacology Vol. 190 (ed. Beitz, E.) (Springer, 2009).
Noda, Y. & Sasaki, S. Trafficking mechanism of water channel aquaporin-2. Biol. Cell 97, 885–892 (2005).
Katsura, T., Gustafson, C. E., Ausiello, D. A. & Brown, D. Protein kinase A phosphorylation is involved in regulated exocytosis of aquaporin-2 in transfected LLC-PK1 cells. Am. J. Physiol. 272, F817–F822 (1997).
Limbutara, K., Kelleher, A., Yang, C. R., Raghuram, V. & Knepper, M. A. Phosphorylation changes in response to kinase inhibitor H89 in PKA-null cells. Sci. Rep. 9, 2814 (2019).
Gilbert, M. L., Yang, L., Su, T. & McKnight, G. S. Expression of a dominant negative PKA mutation in the kidney elicits a diabetes insipidus phenotype. Am. J. Physiol. Renal Physiol. 308, F627–F638 (2015).
Isobe, K. et al. Systems-level identification of PKA-dependent signaling in epithelial cells. Proc. Natl Acad. Sci. USA 114, E8875–E8884 (2017).
Datta, A. et al. PKA-independent vasopressin signaling in renal collecting duct. FASEB J. 34, 6129–6146 (2020).
Bradford, D. et al. Use of LC-MS/MS and Bayes’ theorem to identify protein kinases that phosphorylate aquaporin-2 at Ser256. Am. J. Physiol. Cell Physiol. 307, C123–C139 (2014).
Liwang, J. K. et al. Role of PKC and AMPK in hypertonicity-stimulated water reabsorption in rat inner medullary collecting ducts. Am. J. Physiol. Renal Physiol. 316, F253–F262 (2019).
Al-Bataineh, M. M. et al. Activation of the metabolic sensor AMP-activated protein kinase inhibits aquaporin-2 function in kidney principal cells. Am. J. Physiol. Renal Physiol. 311, F890–F900 (2016).
Klein, J. D. et al. Metformin, an AMPK activator, stimulates the phosphorylation of aquaporin 2 and urea transporter A1 in inner medullary collecting ducts. Am. J. Physiol. Renal Physiol. 310, F1008–F1012 (2016).
Efe, O., Klein, J. D., LaRocque, L. M., Ren, H. & Sands, J. M. Metformin improves urine concentration in rodents with nephrogenic diabetes insipidus. JCI Insight 1, e88409 (2016).
Bech, A. P., Wetzels, J. F. M. & Nijenhuis, T. Effects of sildenafil, metformin, and simvastatin on ADH-independent urine concentration in healthy volunteers. Physiol. Rep. 6, e13665 (2018).
Olesen, E. T. & Fenton, R. A. Aquaporin-2 membrane targeting: still a conundrum. Am. J. Physiol. Renal Physiol. 312, F744–F747 (2017).
Zhang, J. Z. et al. Phase separation of a PKA regulatory subunit controls cAMP compartmentation and oncogenic signaling. Cell 182, 1531–1544.e15 (2020).
Bock, A. et al. Optical mapping of cAMP signaling at the nanometer scale. Cell 182, 1519–1530.e17 (2020).
Stefan, E. et al. Compartmentalization of cAMP-dependent signaling by phosphodiesterase-4D is involved in the regulation of vasopressin-mediated water reabsorption in renal principal cells. J. Am. Soc. Nephrol. 18, 199–212 (2007).
Liu, S. et al. Phosphodiesterases coordinate cAMP propagation induced by two stimulatory G protein-coupled receptors in hearts. Proc. Natl Acad. Sci. USA 109, 6578–6583 (2012).
Omar, M. H. & Scott, J. D. AKAP signaling islands: venues for precision pharmacology. Trends Pharmacol. Sci. 41, 933–946 (2020).
Wingler, L. M. & Lefkowitz, R. J. Conformational basis of G protein-coupled receptor signaling versatility. Trends Cell Biol. 30, 736–747 (2020).
Olesen, E. T., Moeller, H. B., Assentoft, M., MacAulay, N. & Fenton, R. A. The vasopressin type 2 receptor and prostaglandin receptors EP2 and EP4 can increase aquaporin-2 plasma membrane targeting through a cAMP-independent pathway. Am. J. Physiol. Renal Physiol. 311, F935–F944 (2016).
Brunton, L. L., Hayes, J. S. & Mayer, S. E. Hormonally specific phosphorylation of cardiac troponin I and activation of glycogen phosphorylase. Nature 280, 78–80 (1979).
Hayes, J. S., Brunton, L. L. & Mayer, S. E. Selective activation of particulate cAMP-dependent protein kinase by isoproterenol and prostaglandin E1. J. Biol. Chem. 255, 5113–5119 (1980).
Henn, V. et al. Identification of a novel A-kinase anchoring protein 18 isoform and evidence for its role in the vasopressin-induced aquaporin-2 shuttle in renal principal cells. J. Biol. Chem. 279, 26654–26665 (2004).
Klussmann, E., Maric, K., Wiesner, B., Beyermann, M. & Rosenthal, W. Protein kinase A anchoring proteins are required for vasopressin-mediated translocation of aquaporin-2 into cell membranes of renal principal cells. J. Biol. Chem. 274, 4934–4938 (1999).
Ando, F. et al. AKAPs-PKA disruptors increase AQP2 activity independently of vasopressin in a model of nephrogenic diabetes insipidus. Nat. Commun. 9, 1411 (2018).
Christian, F. et al. Small molecule AKAP-protein kinase A (PKA) interaction disruptors that activate PKA interfere with compartmentalized cAMP signaling in cardiac myocytes. J. Biol. Chem. 286, 9079–9096 (2011).
Friedrich, M. W., Aramuni, G., Mank, M., Mackinnon, J. A. & Griesbeck, O. Imaging CREB activation in living cells. J. Biol. Chem. 285, 23285–23295 (2010).
Wang, Y., Chen, Y., Chen, M. & Xu, W. AKAPs competing peptide HT31 disrupts the inhibitory effect of PKA on RhoA activity. Oncol. Rep. 16, 755–761 (2006).
Schrade, K. et al. An AKAP-Lbc-RhoA interaction inhibitor promotes the translocation of aquaporin-2 to the plasma membrane of renal collecting duct principal cells. PLoS ONE 13, e0191423 (2018).
Cheung, P. W., Terlouw, A., Janssen, S. A., Brown, D. & Bouley, R. Inhibition of non-receptor tyrosine kinase Src induces phosphoserine 256-independent aquaporin-2 membrane accumulation. J. Physiol. 597, 1627–1642 (2019).
Hill, J., Shields, J. & Passero, V. Tyrosine kinase inhibitor-associated syndrome of inappropriate secretion of anti-diuretic hormone. J. Oncol. Pharm. Pract. 22, 729–732 (2016).
Ando, F. et al. Wnt5a induces renal AQP2 expression by activating calcineurin signalling pathway. Nat. Commun. 7, 13636 (2016).
Bogum, J. et al. Small-molecule screening identifies modulators of aquaporin-2 trafficking. J. Am. Soc. Nephrol. 24, 744–758 (2013).
Mortensen, L. A., Bistrup, C., Jensen, B. L. & Hinrichs, G. R. A mini-review of pharmacological strategies used to ameliorate polyuria associated with X-linked nephrogenic diabetes insipidus. Am. J. Physiol. Renal Physiol. 319, F746–F753 (2020).
Nomura, N. et al. High-throughput chemical screening identifies AG-490 as a stimulator of aquaporin 2 membrane expression and urine concentration. Am. J. Physiol. Cell Physiol. 307, C597–C605 (2014).
Gow, C. B. & Phillips, P. A. Epidermal growth factor as a diuretic in sheep. J. Physiol. 477, 27–33 (1994).
Cheung, P. W. et al. EGF receptor inhibition by erlotinib increases aquaporin 2-mediated renal water reabsorption. J. Am. Soc. Nephrol. 27, 3105–3116 (2016).
Gabow, P. A. Autosomal dominant polycystic kidney disease. N. Engl. J. Med. 329, 332–342 (1993).
Hajji, M. et al. Clinical study on autosomal dominant polycystic kidney disease among North Tunisians. Saudi J. Kidney Dis. Transpl. 30, 175–184 (2019).
Chebib, F. T. et al. A practical guide for treatment of rapidly progressive ADPKD with tolvaptan. J. Am. Soc. Nephrol. 29, 2458–2470 (2018).
Hildebrandt, F., Benzing, T. & Katsanis, N. Ciliopathies. N. Engl. J. Med. 364, 1533–1543 (2011).
Douguet, D., Patel, A. & Honore, E. Structure and function of polycystins: insights into polycystic kidney disease. Nat. Rev. Nephrol. 15, 412–422 (2019).
Leipziger, J. & Praetorius, H. A. Renal autocrine and paracrine signaling: a story of self-protection. Physiol. Rev. 100, 1229–1289 (2020).
Svenningsen, P., Burford, J. L. & Peti-Peterdi, J. ATP releasing connexin 30 hemichannels mediate flow-induced calcium signaling in the collecting duct. Front. Physiol. 4, 292 (2013).
Xu, C. et al. Human ADPKD primary cyst epithelial cells with a novel, single codon deletion in the PKD1 gene exhibit defective ciliary polycystin localization and loss of flow-induced Ca2+ signaling. Am. J. Physiol. Renal Physiol. 292, F930–F945 (2007).
Shibazaki, S. et al. Cyst formation and activation of the extracellular regulated kinase pathway after kidney specific inactivation of Pkd1. Hum. Mol. Genet. 17, 1505–1516 (2008).
Ma, M., Tian, X., Igarashi, P., Pazour, G. J. & Somlo, S. Loss of cilia suppresses cyst growth in genetic models of autosomal dominant polycystic kidney disease. Nat. Genet. 45, 1004–1012 (2013).
Yang, B., Sonawane, N. D., Zhao, D., Somlo, S. & Verkman, A. S. Small-molecule CFTR inhibitors slow cyst growth in polycystic kidney disease. J. Am. Soc. Nephrol. 19, 1300–1310 (2008).
Zhang, Y. et al. Genetic deletion of P2Y2 receptor offers long-term (5 months) protection against lithium-induced polyuria, natriuresis, kaliuresis, and collecting duct remodeling and cell proliferation. Front. Physiol. 9, 1765 (2018).
Sullivan, L. P., Wallace, D. P. & Grantham, J. J. Epithelial transport in polycystic kidney disease. Physiol. Rev. 78, 1165–1191 (1998).
Menezes, L. F. & Germino, G. G. The pathobiology of polycystic kidney disease from a metabolic viewpoint. Nat. Rev. Nephrol. 15, 735–749 (2019).
Cornec-Le Gall, E., Alam, A. & Perrone, R. D. Autosomal dominant polycystic kidney disease. Lancet 393, 919–935 (2019).
Cai, J. et al. A RhoA-YAP-c-Myc signaling axis promotes the development of polycystic kidney disease. Genes Dev. 32, 781–793 (2018).
Shillingford, J. M., Piontek, K. B., Germino, G. G. & Weimbs, T. Rapamycin ameliorates PKD resulting from conditional inactivation of Pkd1. J. Am. Soc. Nephrol. 21, 489–497 (2010).
Shillingford, J. M. et al. The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease. Proc. Natl Acad. Sci. USA 103, 5466–5471 (2006).
Streets, A. J., Prosseda, P. P. & Ong, A. C. Polycystin-1 regulates ARHGAP35-dependent centrosomal RhoA activation and ROCK signaling. JCI Insight 5, e135385 (2020).
Serra, A. L. et al. Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. N. Engl. J. Med. 363, 820–829 (2010).
Walz, G. et al. Everolimus in patients with autosomal dominant polycystic kidney disease. N. Engl. J. Med. 363, 830–840 (2010).
Yanda, M. K., Cha, B., Cebotaru, C. V. & Cebotaru, L. Pharmacological reversal of renal cysts from secretion to absorption suggests a potential therapeutic strategy for managing autosomal dominant polycystic kidney disease. J. Biol. Chem. 294, 17090–17104 (2019).
Yanda, M. K., Liu, Q. & Cebotaru, L. A potential strategy for reducing cysts in autosomal dominant polycystic kidney disease with a CFTR corrector. J. Biol. Chem. 293, 11513–11526 (2018).
Graffe, C. C., Bech, J. N., Lauridsen, T. G. & Pedersen, E. B. Urinary excretion of AQP2 and ENaC in autosomal dominant polycystic kidney disease during basal conditions and after a hypertonic saline infusion. Am. J. Physiol. Renal Physiol. 302, F917–F927 (2012).
Chen, Y. et al. Aquaporin 2 promotes cell migration and epithelial morphogenesis. J. Am. Soc. Nephrol. 23, 1506–1517 (2012).
Verschuren, E. H. J. et al. Polycystin-1 dysfunction impairs electrolyte and water handling in a renal precystic mouse model for ADPKD. Am. J. Physiol. Renal Physiol. 315, F537–F546 (2018).
Reif, G. A. et al. Tolvaptan inhibits ERK-dependent cell proliferation, Cl− secretion, and in vitro cyst growth of human ADPKD cells stimulated by vasopressin. Am. J. Physiol. Renal Physiol. 301, F1005–F1013 (2011).
Wang, Q. et al. Adenylyl cyclase 5 deficiency reduces renal cyclic AMP and cyst growth in an orthologous mouse model of polycystic kidney disease. Kidney Int. 93, 403–415 (2018).
Rees, S. et al. Adenylyl cyclase 6 deficiency ameliorates polycystic kidney disease. J. Am. Soc. Nephrol. 25, 232–237 (2014).
Pinto, C. S., Reif, G. A., Nivens, E., White, C. & Wallace, D. P. Calmodulin-sensitive adenylyl cyclases mediate AVP-dependent cAMP production and Cl− secretion by human autosomal dominant polycystic kidney cells. Am. J. Physiol. Renal Physiol. 303, F1412–F1424 (2012).
Sherpa, R. T. et al. Sensory primary cilium is a responsive cAMP microdomain in renal epithelia. Sci. Rep. 9, 6523 (2019).
Tesar, V. et al. Bosutinib versus placebo for autosomal dominant polycystic kidney disease. J. Am. Soc. Nephrol. 28, 3404–3413 (2017).
Cadnapaphornchai, M. A. et al. Effect of pravastatin on total kidney volume, left ventricular mass index, and microalbuminuria in pediatric autosomal dominant polycystic kidney disease. Clin. J. Am. Soc. Nephrol. 9, 889–896 (2014).
Leonhard, W. N. et al. Salsalate, but not metformin or canagliflozin, slows kidney cyst growth in an adult-onset mouse model of polycystic kidney disease. EBioMedicine 47, 436–445 (2019).
Lian, X. et al. The combination of metformin and 2-deoxyglucose significantly inhibits cyst formation in miniature pigs with polycystic kidney disease. Br. J. Pharmacol. 176, 711–724 (2019).
Takiar, V. et al. Activating AMP-activated protein kinase (AMPK) slows renal cystogenesis. Proc. Natl Acad. Sci. USA 108, 2462–2467 (2011).
Pisani, A., Riccio, E., Bruzzese, D. & Sabbatini, M. Metformin in autosomal dominant polycystic kidney disease: experimental hypothesis or clinical fact? BMC Nephrol. 19, 282 (2018).
Nikonova, A. S. et al. Opposing effects of inhibitors of aurora-A and EGFR in autosomal-dominant polycystic kidney disease. Front. Oncol. 5, 228 (2015).
Collins, L. M., Moore, R. & Sobel, J. D. Prognosis and long-term outcome of women with idiopathic recurrent vulvovaginal candidiasis caused by candida albicans. J. Low. Genit. Tract Dis. 24, 48–52 (2020).
Ye, H. et al. The regulatory 1alpha subunit of protein kinase A modulates renal cystogenesis. Am. J. Physiol. Renal Physiol. 313, F677–F686 (2017).
Huang, P., Trotter, K., Boucher, R. C., Milgram, S. L. & Stutts, M. J. PKA holoenzyme is functionally coupled to CFTR by AKAPs. Am. J. Physiol. Cell Physiol. 278, C417–C422 (2000).
Fenton, R. A., Murali, S. K. & Moeller, H. B. Advances in aquaporin-2 trafficking mechanisms and their implications for treatment of water balance disorders. Am. J. Physiol. Cell Physiol. 319, C1–C10 (2020).
The authors’ research is supported by the Danish Medical Research Council, The Novo Nordisk Foundation, The Leducq Foundation and the Carlsberg Foundation.
The authors declare no competing interests.
Peer review information
Nature Reviews Nephrology thanks T.-H. Kwon, V. Torres and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
- Single effect
The difference in osmotic pressure that is created by the active transport of sodium chloride out of the tubular fluid in the thick ascending limb into the interstitium; the hyperosmotic gradient in the interstitium drives the passive movement of water from the tubular fluid of the descending limbs and collecting ducts into the interstitium.
- Recycling endosomes
Organelles in the endocytic pathway, in which plasma membrane proteins and lipids that are internalized by endocytosis are sorted and processed for export back to the cell surface for reuse.
The transport of macromolecular cargo from one side of a cell to the other within a membrane-bounded carrier (or carriers); this mechanism is used by multicellular organisms to selectively move material between two environments without altering their unique compositions.
- Multivesicular bodies
(MVBs). Specialized endosomes that contain membrane-bound intraluminal vesicles formed by budding of the membrane into the lumen of the MVB; MVBs can fuse with lysosomes, where their contents are degraded, or they can fuse with the plasma membrane for their contents to be released into the extracellular space.
- K63-linked polyubiquitin chain
A chain of ubiquitin molecules that are linked to each other on Lys63 (one of seven lysine residues within ubiquitin) to form a long polyubiquitin chain; these chains can mark the ubiquitylated protein for endocytosis.
A filamentous polymer composed of soluble G-actin monomers; it is the most abundant component of the cytoskeleton of eukaryotes.
- CFTR corrector
A family of compounds that facilitate the transport of misfolded CFTR proteins (produced owing to mutations in CFTR) to the cell membrane without being degraded.
About this article
Cite this article
Olesen, E.T.B., Fenton, R.A. Aquaporin 2 regulation: implications for water balance and polycystic kidney diseases. Nat Rev Nephrol 17, 765–781 (2021). https://doi.org/10.1038/s41581-021-00447-x
Pflügers Archiv - European Journal of Physiology (2022)